Collecting high-quality data is critical to addressing healthcare equity issues, according to Marcella Nunez-Smith, M.D., M.H.S., whom President-elect Joe Biden has chosen to lead a new White House task force on the issue.
Collecting high-quality data is critical to addressing healthcare equity issues, according to Marcella Nunez-Smith, M.D., M.H.S., whom President-elect Joe Biden has chosen to lead a new White House task force on the issue.
“There is violence in data invisibility. We cannot address what we cannot see,” Nunez-Smith, an associate professor of medicine and epidemiology at the Yale School of Medicine, said during an online forum on racism and discrimination in healthcare last month that was sponsored by Kaiser Family Foundation and the Morehouse School of Medicine’s Satcher Health Leadership Institute. “We are making a choice every time we allow poor quality to hinder our ability to intervene on racial and ethnic minorities.”
Nunez-Smith discussed the lack of compliance with a requirements that race and ethnic group information be included when COVID-19 cases are reported to public health officials and a similar absence in data about COVID-19 testing.
Nunez-Smith, whom Biden appointed earlier to be one of three co-chairs of his COVID-19 task force, also mentioned representation in the physician workforce and collection of data about patients’ experiences of discrimination as crucial to addressing healthcare inequities.
“Healthcare is a right, not a privilege. Healthcare free from racism and discrimination is a right, not a privilege,” she said.
2023 Drug Trend Report - Xevant
May 16th 2024To effectively navigate the changing pharmacy landscape and maintain a robust, cost-effective pharmacy benefit, you must understand the forces behind rising drug trend. What’s driving your costs and what can you do about it? As a leader in the PBM analytics space, we offer a unique perspective on pivotal trend drivers. Here’s what our comprehensive analysis revealed: -A surge in utilization rates across specialty and non-specialty drugs, magnified by anti-obesity therapies -Financial strain imposed by anti-inflammatory biologics and the yet-to-be-fulfilled -promise of biosimilar savings -Persistent price inflation driving higher costs year over year
Read More